GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Altman Z-Score

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Altman Z-Score : -23.02 (As of May. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -23.02 is in distress zone. This implies bankruptcy possibility in the next two years.

SQZ Biotechnologies Co has a Altman Z-Score of -23.02, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for SQZ Biotechnologies Co's Altman Z-Score or its related term are showing as below:

SQZB' s Altman Z-Score Range Over the Past 10 Years
Min: -23.02   Med: -2   Max: 3.43
Current: -23.02

During the past 5 years, SQZ Biotechnologies Co's highest Altman Z-Score was 3.43. The lowest was -23.02. And the median was -2.00.


SQZ Biotechnologies Co Altman Z-Score Historical Data

The historical data trend for SQZ Biotechnologies Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQZ Biotechnologies Co Altman Z-Score Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
- - 3.43 - -5.40

SQZ Biotechnologies Co Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 -5.40 -7.96 -11.47 -23.00

Competitive Comparison of SQZ Biotechnologies Co's Altman Z-Score

For the Biotechnology subindustry, SQZ Biotechnologies Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQZ Biotechnologies Co's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Altman Z-Score falls into.



SQZ Biotechnologies Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

SQZ Biotechnologies Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1093+1.4*-11.1813+3.3*-2.4051+0.6*0.0527+1.0*0.4094
=-23.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $29.79 Mil.
Total Current Assets was $12.09 Mil.
Total Current Liabilities was $8.83 Mil.
Retained Earnings was $-333.07 Mil.
Pre-Tax Income was -23.639 + -16.77 + -17.687 + -13.547 = $-71.64 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Revenue was 0 + 0.178 + 0 + 12.018 = $12.20 Mil.
Market Cap (Today) was $1.47 Mil.
Total Liabilities was $27.91 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(12.087 - 8.832)/29.788
=0.1093

X2=Retained Earnings/Total Assets
=-333.07/29.788
=-11.1813

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-71.643 - 0)/29.788
=-2.4051

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1.472/27.907
=0.0527

X5=Revenue/Total Assets
=12.196/29.788
=0.4094

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

SQZ Biotechnologies Co has a Altman Z-Score of -23.02 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


SQZ Biotechnologies Co  (OTCPK:SQZB) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


SQZ Biotechnologies Co Altman Z-Score Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
Executives
Richard Capasso officer: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren officer: Chief Medical Officer C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman director, 10 percent owner PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j. director ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc. 10 percent owner 1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016 10 percent owner C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei director, officer: President and CEO C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Headlines

From GuruFocus